Activin signalling and pre-eclampsia: From genetic risk to pre-symptomatic biomarker

Cytokine

Volumn 71, Issue 2, 2015, Pages 360-365

  Williamson, Rachel D ^a   O'Keeffe, Gerard W ^a,b   Kenny, Louise C ^a  

^a Irish Centre for Fetal and Neonatal Translational Research   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Activin A; ACVR2A; Biomarker; Pre eclampsia; Serum

Indexed keywords

ACTIVIN; ACTIVIN A RECEPTOR TYPE IIA; ACTIVIN RECEPTOR; BIOLOGICAL MARKER; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CYTOKINE;

CYTOKINE PRODUCTION; GENETIC POLYMORPHISM; GENETIC RISK; HIGH RISK POPULATION; HUMAN; INFLAMMATION; MOLECULAR PATHOLOGY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLACENTA FUNCTION; PREECLAMPSIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; CLINICAL TRIAL (TOPIC); FEMALE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PHYSIOLOGY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RISK FACTOR;

ACTIVINS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; OXIDATIVE STRESS; PLACENTA; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84921287110     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.11.017     Document Type: Review

References (75)

1. Steegers E.A.P., von Dadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet 2010, 376:631-644.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009, 33:130-137.
3. Khan K.S., Wojdyla D., Say L., Gulmezoglu A.M., Van Look P.F. WHO analysis of causes of maternal death: a systematic review. Lancet 2006, 367:1066-1074.
4. Founds S.A., Conley Y.P., Lyons-Weiler J.F., Jeyabalan A., Hogge W.A., Conrad K.P. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta 2009, 30:15-24.
5. Hutcheon J.A., Lisonkova S., Joseph K.S. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet 2011, 25:391-403.
6. Chaiworapongsa T., Chaemsaithong P., Yeo L., Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014.
7. Morrish D.W., Dakour J., Li H. Functional regulation of human trophoblast differentiation. J Reprod Immunol 1998, 39:179-195.
8. Huppertz B. The anatomy of the normal placenta. J Clin Pathol 2008, 61:1296-1302.
9. Pijnenborg R., Vercruysse L., Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta 2006, 27:939-958.
10. Cunningham F.G., Williams J.W. Williams obstetrics 2010, McGraw-Hill Medical, New York. 23rd ed. F. Gary Cunningham (Ed.).
11. Zhou Y., Damsky C.H., Fisher S.J. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. J Clin Invest 1997, 99:2152-2164.
12. Weiss A., Attisano L. The TGFbeta superfamily signaling pathway. Wiley Interdiscipl Rev Dev Biol 2013, 2:47-63.
13. Herpin A., Lelong C., Favrel P. Transforming growth factor-beta-related proteins: an ancestral and widespread superfamily of cytokines in metazoans. Dev Comp Immunol 2004, 28:461-485.
14. Matzuk M.M., Kumar T.R., Vassalli A., Bickenbach J.R., Roop D.R., Jaenisch R., et al. Functional analysis of activins during mammalian development. Nature 1995, 374:354-356.
15. Muttukrishna S., Knight P.G., Groome N.P. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 1997, 349:1285-1288.
16. Phillips D.J. Activins, inhibins and follistatins in the large domestic species. Domest Anim Endocrinol 2005, 28:1-16.
17. Hinck A.P. Structural studies of the TGF-betas and their receptors - insights into evolution of the TGF-beta superfamily. FEBS Lett 2012, 586:1860-1870.
18. Roberts-Galbraith R.H., Newmark P.A. Follistatin antagonizes activin signaling and acts with notum to direct planarian head regeneration. Proc Natl Acad Sci USA 2013, 110:1363-1368.
19. Shimonaka M., Inouye S., Shimasaki S., Ling N. Follistatin binds to both activin and inhibin through the common subunit. Endocrinology 1991, 128:3313-3315.
20. Petraglia F., Florio P., Luisi S., Gallo R., Gadducci A., Vigano P., et al. Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 1998, 83:1194-1200.
21. Jones R.L., Salamonsen L.A., Critchley H.O., Rogers P.A., Affandi B., Findlay J.K. Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception. Mol Human Reprod 2000, 6:1107-1117.
22. Yokoyama Y., Nakamura T., Nakamura R., Irahara M., Aono T., Sugino H. Identification of activins and follistatin proteins in human follicular fluid and placenta. J Clin Endocrinol Metab 1995, 80:915-921.
23. de Kretser D.M., Foulds L.M., Hancock M., Robertson D.M. Partial characterization of inhibin, activin, and follistatin in the term human placenta. J Clin Endocrinol Metab 1994, 79:502-507.
24. Shinozaki H., Minegishi T., Nakamura K., Tano M., Miyamoto K., Ibuki Y. Type II and type IIB activin receptors in human placenta. Life Sci 1995, 56:1699-1706.
25. Peng C., Huang T.H., Jeung E.B., Donaldson C.J., Vale W.W., Leung P.C. Expression of the type II activin receptor gene in the human placenta. Endocrinology 1993, 133:3046-3049.
26. Rabinovici J., Goldsmith P.C., Librach C.L., Jaffe R.B. Localization and regulation of the activin-A dimer in human placental cells. J Clin Endocrinol Metab 1992, 75:571-576.
27. Peng C., Mukai S.T. Activins and their receptors in female reproduction. Biochemistry and cell biology = Biochimie et biologie cellulaire 2000, 78:261-279.
28. Jones R.L., Salamonsen L.A., Findlay J.K. Activin A promotes human endometrial stromal cell decidualization in vitro. J clin Endocrinol Metab 2002, 87:4001-4004.
29. Caniggia I., Lye S.J., Cross J.C. Activin is a local regulator of human cytotrophoblast cell differentiation. Endocrinology 1997, 138:3976-3986.
30. Jones R.L., Stoikos C., Findlay J.K., Salamonsen L.A. TGF-beta superfamily expression and actions in the endometrium and placenta. Reproduction 2006, 132:217-232.
31. Natale D.R., Hemberger M., Hughes M., Cross J.C. Activin promotes differentiation of cultured mouse trophoblast stem cells towards a labyrinth cell fate. Dev Biol 2009, 335:120-131.
32. Duckitt K., Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005, 330:565.
33. Ching T., Song M.A., Tiirikainen M., Molnar J., Berry M., Towner D., et al. Genome-wide hypermethylation coupled with promoter hypomethylation in the chorioamniotic membranes of early onset pre-eclampsia. Mol Human Reprod 2014, 20:885-904.
34. Maccani M.A., Marsit C.J. Epigenetics in the placenta. Am J Reprod Immunol 2009, 62:78-89.
35. Poon L.C., Kametas N.A., Chelemen T., Leal A., Nicolaides K.H. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Human Hypertens 2010, 24:104-110.
36. Thompson M.L., Ananth C.V., Jaddoe V.W., Miller R.S., Williams M.A. The association of maternal adult weight trajectory with preeclampsia and gestational diabetes mellitus. Paediatr Perinat Epidemiol 2014, 28:287-296.
37. Allen R., Rogozinska E., Sivarajasingam P., Khan K.S., Thangaratinam S. Effect of diet and life style based metabolic risk modifying interventions on preeclampsia: a meta-analysis. Acta Obstet Gynecol Scand 2014, 00.
38. National Collaborating Centre for Ws, Children's H. National Institute for Health and Clinical Excellence: Guidance. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: RCOG Press Royal College of Obstetricians and Gynaecologists; 2010.
39. England L.J., Levine R.J., Qian C., Morris C.D., Sibai B.M., Catalano P.M., et al. Smoking before pregnancy and risk of gestational hypertension and preeclampsia. Am J Obstet Gynecol 2002, 186:1035-1040.
40. Kanayama N., Tsujimura R., She L., Maehara K., Terao T. Cold-induced stress stimulates the sympathetic nervous system, causing hypertension and proteinuria in rats. J Hypertens 1997, 15:383-389.
41. Minassian C., Thomas S.L., Williams D.J., Campbell O., Smeeth L. Acute maternal infection and risk of pre-eclampsia: a population-based case-control study. PloS one 2013, 8:e73047.
42. Fong F.M., Sahemey M.K., Hamedi G., Eyitayo R., Yates D., Kuan V., et al. Maternal genotype and severe preeclampsia: a HuGE review. Am J Epidemiol 2014, 180:335-345.
43. van Dijk M., Mulders J., Poutsma A., Konst A.A., Lachmeijer A.M., Dekker G.A., et al. Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nat Genet 2005, 37:514-519.
44. Doridot L., Chatre L., Ducat A., Vilotte J.L., Lombes A., Mehats C., et al. Nitroso-redox balance and mitochondrial homeostasis are regulated by STOX1, a pre-eclampsia-associated gene. Antioxidants Redox Signal 2014, 21:819-834.
45. George E.M., Bidwell G.L. STOX1: a new player in preeclampsia?. Hypertension 2013, 61:561-563.
46. Moses E.K., Fitzpatrick E., Freed K.A., Dyer T.D., Forrest S., Elliott K., et al. Objective prioritization of positional candidate genes at a quantitative trait locus for pre-eclampsia on 2q22. Mol Human Reprod 2006, 12:505-512.
47. Arngrimsson R., Siguroardottir S., Frigge M.L., Bjarnadottir R.I., Jonsson T., Stefansson H., et al. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Human Mol Genet 1999, 8:1799-1805.
48. Fitzpatrick E., Johnson M.P., Dyer T.D., Forrest S., Elliott K., Blangero J., et al. Genetic association of the activin A receptor gene (ACVR2A) and pre-eclampsia. Mol Human Reprod 2009, 15:195-204.
49. Roten L.T., Johnson M.P., Forsmo S., Fitzpatrick E., Dyer T.D., Brennecke S.P., et al. Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study). Eur J Human Genet: EJHG 2009, 17:250-257.
50. Lokki A.I., Klemetti M.M., Heino S., Hiltunen L., Heinonen S., Laivuori H. Association of the rs1424954 polymorphism of the ACVR2A gene with the risk of pre-eclampsia is not replicated in a Finnish study population. BMC Res Notes 2011, 4:545.
51. Hubel C.A. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 1999, 222:222-235.
52. Wallace E.M., Schneider-Kolsky M.E., Edwards A., Baker L., Jenkin G. Maternal serum activin A levels in association with intrauterine fetal growth restriction. BJOG: Int J Obstet Gynaecol 2003, 110:306-310.
53. Valko M., Morris H., Cronin M.T. Metals, toxicity and oxidative stress. Curr Med Chem 2005, 12:1161-1208.
54. Mandang S., Manuelpillai U., Wallace E.M. Oxidative stress increases placental and endothelial cell activin A secretion. J Endocrinol 2007, 192:485-493.
55. Cotechini T., Komisarenko M., Sperou A., Macdonald-Goodfellow S., Adams M.A., Graham C.H. Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia. J Exp Med 2014, 211:165-179.
56. Tannetta D.S., Muttukrishna S., Groome N.P., Redman C.W., Sargent I.L. Endothelial cells and peripheral blood mononuclear cells are a potential source of extraplacental activin a in preeclampsia. J Clin Endocrinol Metabol 2003, 88:5995-6001.
57. Mohan A., Asselin J., Sargent I.L., Groome N.P., Muttukrishna S. Effect of cytokines and growth factors on the secretion of inhibin A, activin A and follistatin by term placental villous trophoblasts in culture. Eur J Endocrinol/Eur Fed Endocr Soc 2001, 145:505-511.
58. Redman C.W., Sacks G.P., Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999, 180:499-506.
59. Wallace E.M., Marjono B., Tyzack K., Tong S. First trimester levels of inhibins and activin A in normal and failing pregnancies. Clin Endocrinol 2004, 60:484-490.
60. Malone F.D., Canick J.A., Ball R.H., Nyberg D.A., Comstock C.H., Bukowski R., et al. First-trimester or second-trimester screening, or both, for Down's syndrome. New Engl J Med 2005, 353:2001-2011.
61. Bersinger N.A., Smarason A.K., Muttukrishna S., Groome N.P., Redman C.W. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Preg: Off J Int Soc Study Hypertens Preg 2003, 22:45-55.
62. Giguere Y., Charland M., Bujold E., Bernard N., Grenier S., Rousseau F., et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2010, 56:361-375.
63. Spencer K., Cowans N.J., Nicolaides K.H. Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol: Off J Int Soc Ultrasound Obstet Gynecol 2008, 32:622-626.
64. Petraglia F., Aguzzoli L., Gallinelli A., Florio P., Zonca M., Benedetto C., et al. Hypertension in pregnancy: changes in activin A maternal serum concentration. Placenta 1995, 16:447-454.
65. Silver H.M., Lambert-Messerlian G.M., Star J.A., Hogan J., Canick J.A. Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies. Am J Obstet Gynecol 1999, 180:1131-1137.
66. Muttukrishna S., Hyett J., Paine M., Moodley J., Groome N., Rodeck C. Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients. Clin Endocrinol 2006, 64:469-473.
67. Akolekar R., Etchegaray A., Zhou Y., Maiz N., Nicolaides K.H. Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther 2009, 25:320-327.
68. Diesch C.H., Holzgreve W., Hahn S., Zhong X.Y. Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenatal Diagn 2006, 26:1267-1270.
69. Florio P., Ciarmela P., Luisi S., Palumbo M.A., Lambert-Messerlian G., Severi F.M., et al. Pre-eclampsia with fetal growth restriction: placental and serum activin A and inhibin A levels. Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol 2002, 16:365-372.
70. Khalil A., Jauniaux E., Harrington K., Muttukrishna S. Placental production and maternal serum and urine levels of inhibin A and activin A are modified by antihypertensive therapy in hypertensive disorders of pregnancy. Clin Endocrinol 2009, 70:924-931.
71. Muttukrishna S., Child T.J., Groome N.P., Ledger W.L. Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy. Human Reprod 1997, 12:1089-1093.
72. Navaratnam K., Alfirevic Z., Baker P.N., Gluud C., Gruttner B., Kublickiene K., et al. A multi-centre phase IIa clinical study of predictive testing for preeclampsia: improved pregnancy outcomes via early detection (IMPROvED). BMC Preg Childbirth 2013, 13:226.
73. Lai J., Pinas A., Syngelaki A., Poon L.C., Nicolaides K.H. Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia. J Matern Fetal Neonatal Med 2013, 26:733-737.
74. Vambergue A., Fajardy I. Consequences of gestational and pregestational diabetes on placental function and birth weight. World J Diabetes 2011, 2:196-203.
75. Scifres C.M., Nelson D.M. Intrauterine growth restriction, human placental development and trophoblast cell death. J Physiol 2009, 587:3453-3458.